Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

1-33. (Cancelled).

34. (Previously amended) A sustained release formulation of lamotrigine or a pharmaceutically acceptable derivative thereof comprising a matrix tablet in which there are two phases in the release of lamotrigine or a pharmaceutically acceptable derivative thereof, wherein the release rate in the first phase takes place in the oesophagus and stomach and is slower than the release rate in the second phase which takes place when the surrounding pH exceeds 5, further comprising

1) a core comprising:

a) 2.5 to 80% by weight lamotrigine or a pharmaceutically acceptable derivative thereof;

b) 17.5 to 70% by weight release retarding polymer;

c) 0 to 60 % by weight diluent;

d) 0 to 20 % by weight compression aid; and

e) 0.1 to 2.5% by weight lubricants;

and an outer coat comprising

f) 0.05 mm to 0.30 mm of polymer;

2) an outer coating covering said core, the thickness of said outer coating being adapted such that it is substantially impermeable to the entrance of an environmental fluid and substantially impermeable to the exit of lamotrigine or a pharmaceutically acceptable derivative thereof, and wherein said outer coating dissolves when the surrounding pH exceeds 5; and

3) said outer coating including one or more orifices extending from the

outside of the coating substantially completely through said coating but not penetrating said core allowing the release of lamotrigine or a pharmaceutically acceptable derivative thereof from the core into enviromental fluid, said orifices having an area or combined area from about 10 to about 60 percent of the face area of said formulation, wherein the release of lamotrigine or a pharmaceutically acceptable derivative thereof occurs substantially through said orifice.

35 - 41 (Cancelled).

42. (Previously Presented) A sustained release formulation as claimed in claim 34 which upon administration to a human produce AUC values within the range of 80 to 125% and a C_{max} being of about 30% less than an instant release tablet containing the same amount of lamotrigine or a pharmaceutically acceptable derivative thereof.

43. (Cancelled)

44. (Cancelled)

45. (Previously Presented) A sustained release formulation as claimed in claim 34, wherein said release retarding excipient is a HPMC polymer.

46. (Previously Presented) A sustained release formulation as claimed in claim 34 wherein the outer coat comprises a methacrylic acid copolymer.

47. (New) A sustained release formulation of lamotrigine or a pharmaceutically acceptable derivative thereof comprising a matrix tablet in which there are two phases in the release of lamotrigine or a pharmaceutically acceptable derivative thereof, wherein the release rate in the first phase takes place in the oesophagus and stomach and is slower than the release rate in the

second phase which takes place when the surrounding pH exceeds 5, further comprising

1) a core comprising:

a) 2.5 to 80% by weight lamotrigine or a pharmaceutically acceptable derivative thereof;

b) 17.5 to 70% by weight release retarding polymer;

c) 0 to 60 % by weight diluent;

d) 0 to 20 % by weight compression aid; and

e) 0.1 to 2.5% by weight lubricants;

and an outer coat comprising

f) 0.05 mm to 0.30 mm of polymer;

2) an outer coating covering said core, the thickness of said outer coating being adapted such that it is substantially impermeable to the entrance of an environmental fluid and substantially impermeable to the exit of lamotrigine or a pharmaceutically acceptable derivative thereof, and wherein said outer coating dissolves when the surrounding pH exceeds 5; and

3) said outer coating including one or more orifices extending from the outside of the coating substantially completely through said coating but not penetrating said core allowing the release of lamotrigine or a pharmaceutically acceptable derivative thereof from the core into enviromental fluid, said orifices having an area or combined area from about 10 to about 60 percent of the face area of said formulation, wherein the release of lamotrigine or a pharmaceutically acceptable derivative thereof occurs substantially through said orifice, and said sustained release formulation upon administration to a human produces AUC values within the range of 80 to 125% and a C_{max} being of about 30% less than an instant release tablet containing the same amount of lamotrigine or a pharmaceutically acceptable derivative thereof.